

The *hSSB1* orthologue *Obfc2b* is essential for skeletogenesis but dispensable for the DNA damage response *in vivo*

Niklas Feldhahn^{1,*}, Elisabetta Ferretti²,
Davide F Robbiani¹, Elsa Callen³,
Stephanie Deroubaix¹, Licia Selleri²,
Andre Nussenzweig³ and
Michel C Nussenzweig^{1,4}

¹Laboratory of Molecular Immunology, Rockefeller University, New York, NY, USA, ²Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, NY, USA, ³Laboratory of Genome Integrity, National Cancer Institute National Institutes of Health, Bethesda, MD, USA and ⁴Howard Hughes Medical Institute, Rockefeller University, New York, NY, USA

Human single-stranded DNA-binding protein 1 (hSSB1), encoded by *OBFC2B*, was recently characterized as an essential factor for the initiation of DNA damage checkpoints and the maintenance of genomic stability. Here, we report that loss of *Obfc2b* in mice results in perinatal lethality characterized by growth delay and skeletal abnormalities. These abnormalities are associated with accumulation of γ H2ax, apoptosis and defective pre-cartilage condensation, which is essential for normal bone formation. However, deficiency of *Obfc2b* does not affect the initiation of DNA damage checkpoints, Atm activation, or the maintenance of genomic stability in B lymphocytes and primary fibroblasts. Loss of *Obfc2b* results in increased expression of its homologue *Obfc2a* (*hSSB2*). In contrast to *Obfc2b* deficiency, depletion of *Obfc2a* in fibroblasts results in impaired proliferation, accumulation of γ H2ax and increased genomic instability. Thus, the *hSSB1* orthologue *Obfc2b* has a unique function during embryogenesis limited to cell types that contribute to bone formation. While being dispensable in most other cell lineages, its absence leads to a compensatory increase in *Obfc2a* protein, a homologue required for the maintenance of genomic integrity.

The EMBO Journal (2012) 31, 4045–4056. doi:10.1038/emboj.2012.247; Published online 31 August 2012

Subject Categories: genome stability & dynamics; development

Keywords: apoptosis; DNA damage response; hSSB1; *Obfc2b*; skeletogenesis

Introduction

Nuclear DNA is normally double-stranded, but single-stranded DNA (ssDNA) is exposed during DNA replication, meiosis, transcription, and DNA double-strand break (DSB) repair.

*Corresponding author. Laboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, Box 220, New York, NY 10065, USA. Tel.: +1 212 327 8098; Fax: +1 212 327 8370; E-mail: nfeldhahn@rockefeller.edu

Received: 30 May 2012; accepted: 9 August 2012; published online: 31 August 2012

ssDNA, which is an obligate intermediate in these reactions, is more vulnerable to chemical and physical damage than double-stranded DNA (dsDNA). The increased vulnerability of ssDNA is alleviated in part by ssDNA-binding proteins that stabilize, protect and facilitate the repair of damaged ssDNA (reviewed by Mendez and Stillman, 2003). Underlining their importance, loss of function of the ssDNA-binding protein replication protein A (Rpa1) results in embryonic lethality in mice (Wang *et al*, 2005). Even heterozygous *Rpa1* mutant mice show an increase in genomic instability and develop lymphoid tumours (Wang *et al*, 2005).

Two additional ssDNA-binding proteins, hSSB1 (OBFC2B, NABP2 or SOSS-B1) and hSSB2 (OBFC2A, NABP1 or SOSS-B2), are also thought to be essential for recognition and repair of DNA damage (Richard *et al*, 2008, 2011a, b; Huang *et al*, 2009; Li *et al*, 2009; Zhang *et al*, 2009). Similarly to RPA1, hSSB1 and hSSB2 form heterotrimeric complexes that are required for their recruitment to DSBs (Huang *et al*, 2009; Li *et al*, 2009; Skaar *et al*, 2009; Zhang *et al*, 2009). RNA interference (RNAi) experiments indicated that hSSB1 is essential to induce phosphorylation of ataxia telangiectasia mutated (ATM) kinase and its downstream targets in response to DNA damage. Moreover knockdown of hSSB1 is reported to abrogate irradiation-induced G1/S and G2/M cell-cycle arrest and result in genomic instability (Richard *et al*, 2008; Huang *et al*, 2009; Li *et al*, 2009; Zhang *et al*, 2009). In addition to repair and checkpoint functions, it has been proposed that hSSB1 is also required to produce ssDNA at sites of DSBs and that it does so by recruiting the MRN (MRE11/RAD50/NBS1) complex and the CtBP-interacting protein (CTIP) endonuclease (Richard *et al*, 2011a, b). However, the role of hSSB1 in DNA repair has only been tested in RNAi knockdown experiments in cell lines.

To study the role of the ssDNA-binding protein hSSB1 *in vivo*, we produced conditional knockout mice for the *hSSB1* orthologue *Obfc2b*. We find that *Obfc2b* exhibits an essential, unique and cell type-specific role during embryogenesis. Germline deletion of *Obfc2b* results in increased replication-associated DNA damage and apoptosis in cell types that are essential for skeletal development and, hence, in severe skeletal defects and perinatal lethality. Furthermore, loss of *Obfc2b* results in a compensatory increase of its homologue *Obfc2a* (orthologue to hSSB2). Unexpectedly, these ssDNA-binding proteins are not required to initiate the DNA damage response to irradiation, but play an important tissue-specific role in the suppression of replication-associated DNA damage.

Results

Germline deletion of *Obfc2b* results in embryonic lethality

Human ssDNA-binding protein 1 (hSSB1 or SOSS-B1) is encoded by the *OBFC2B* gene (oligonucleotide/oligosacchar-




Figure 1 Loss of *Obfc2b* results in embryonic lethality and developmental abnormalities. (A) Design of the conditional *Obfc2b* allele. Schematic of the murine *Obfc2b*^{lox} allele with integrated loxP sites before (upper panel), and after Cre-mediated disruption (lower panel) is shown. (B) *Obfc2b* deficiency results in embryonic lethality. Table of genotypes observed from *Obfc2b*^{+/-} intercrosses are shown. (C) *Obfc2b* deficiency results in developmental abnormalities. Appearance of embryos at days E18.5 (left) and P0 (right) is shown. Bar marks size difference and arrows mark developmental abnormalities of the hindlimbs. (D) *Obfc2b* mRNA analysis in wild-type embryos at day E10.5 by *in situ* hybridization. Arrows indicate specific staining at the branchial arches (BAs), neural crest (NC), neural tube (NT), forelimbs (FL) and hindlimbs (HL) and somites (So) using the anti-sense probe. An *Obfc2b* sense probe was used as control (right).

ide-binding fold containing 2B; Supplementary Figure 1A). To conditionally delete *hSSB1*, in mice, we introduced loxP sites flanking exons 1 and 2 of *Obfc2b* in mouse embryonic stem (ES) cells (*Obfc2b*^{lox}; Figure 1A and Supplementary Figure 1B). To generate mice carrying an *Obfc2b* knockout allele, *Obfc2b*^{lox} mice were bred with mice expressing the *EIIA*^{Cre} transgene (Lakso *et al*, 1996; Supplementary Figure 1B and C). Cre-mediated loss of *Obfc2b* protein was confirmed by western blotting of B cells from *CD19*^{Cre}; *Obfc2b*^{lox/-} mice (Supplementary Figure 1D and see below).

To determine whether *Obfc2b* is essential for mouse development, *Obfc2b*^{+/-} mice were interbred. Out of 129 pups analysed at 0–2 weeks of age, we found no viable *Obfc2b*^{-/-} mice even on the day of delivery (P0) (Figure 1B). However, *Obfc2b*^{-/-} embryos were present at nearly Mendelian ratios as late as at embryonic day 18.5 (E18.5, Figure 1B). At this time, the homozygous mutant embryos appeared to be viable but exhibited significant growth delay, rudimentary hin-

dlimbs (HL) and an abnormal skull (Figure 1C). We conclude that loss of *Obfc2b* results in developmental abnormalities during embryogenesis and perinatal death.

To determine whether the developmental abnormalities in *Obfc2b*^{-/-} mice result from a tissue-specific requirement of *Obfc2b* function during embryogenesis, we performed *in situ* hybridization for *Obfc2b* mRNA expression on wild-type E10.5 embryos. *Obfc2b* was expressed in several tissues that contribute to the development of skeletal structures (Figure 1D). These include the limb buds that organize the development of fore- and hindlimbs (FL, HL); the somites (So) which form in part the sclerotome and further the vertebrae and part of the skull; the branchial arches (BAs) that contribute to the development of the mandibles and the palate; and the prospective neural crest (NC) that can give rise to craniofacial mesenchyme and further form craniofacial cartilage and bones. In addition, *Obfc2b* mRNA expression seemed to be specific for the closing neural tube (NT) and different regions of the head (Figure 1D). We conclude that *Obfc2b* shows a tissue-specific expression pattern during normal embryogenesis.

Obfc2b^{-/-} embryos exhibit severe skeletal defects

To characterize skeletal defects in more depth, we visualized cartilage and mineralized bone in E18.5 embryos (Figure 2). *Obfc2b*^{-/-} embryos exhibited severe skeletal abnormalities affecting the rib cage, limbs and skull: the rib cage showed a general decrease in size and ossified rib segments were missing or rudimentary (Figure 2A). Since the lower rib cage serves as an anchor for the thoracic diaphragm, it is likely that the perinatal death of *Obfc2b*^{-/-} embryos is caused by respiratory failure. Micro-computer tomography (MicroCT) analysis of dead *Obfc2b*^{-/-} newborns (P0) confirmed the presence of a rudimentary rib cage and revealed that the bones were thinner and showed increased porosity (Supplementary Figure 2). Furthermore, the skull had a hypoplastic lower mandible (Figure 2B, left), the tympanic ring of the inner ear was rudimentary and the palate was cleft (Figure 2B, right). In the region of the forelimbs, the spine of the scapula and the deltoid tuberosity of the humerus were missing or rudimentary, respectively (Figure 2C, left). There was variable penetrance of skeletal abnormalities in the hindlimbs, which included missing digits (Figure 2C, right). MicroCT of the femurs revealed a significant decrease in bone volume (Supplementary Figure 2B–D). This pattern of skeletal defects is consistent with the pattern of *Obfc2b* expression in wild-type E10.5 embryos described above (Figure 1D). We conclude that *Obfc2b* deficiency results in multiple skeletal defects during embryogenesis.

Osteoblasts, chondrocytes and osteoclasts in *Obfc2b*^{-/-} mice

To determine whether skeletal defects in *Obfc2b*^{-/-} mice arise as a consequence of aberrant differentiation or function of bone forming cells, we isolated osteoblasts, chondrocytes and osteoclasts from wild-type and *Obfc2b*^{-/-} mice. Osteoblasts were isolated from the calvaria of the skull from E18.5 embryos; chondrocytes were isolated from the sternum of the ribcage. Osteoclasts were generated from bone marrow cells by stimulation with RANK-L and M-CSF for 5 days in culture and osteoclast identity was verified by Tartrate-resistant Acidic Phosphatase (TRAP) staining (Supplementary Figure 3A).




Figure 2 Skeletal abnormalities in *Obfc2b*^{-/-} embryos. (A) Rib cage preparations of E18.5 embryos visualized by Alcian blue and Alizarin red staining indicating cartilage (blue) and mineralized/ossified tissue (red). (B) Skull preparations: bars mark size differences in the lower mandible (left) and arrows mark the rudimentary tympanic ring and the cleft palate in skulls from *Obfc2b*^{-/-} embryos (middle and right). (C) Preparations of the forelimbs (left panels) and hindlimbs from wild-type and *Obfc2b*^{-/-} embryos (right panels).

Isolated cells were then subjected to gene expression analysis using gene arrays. Expression of osteoblast-, chondrocyte- and osteoclast-specific genes confirmed the identity of the isolated cell subsets (Supplementary Figure 3B). Comparison of gene arrays from wild-type and *Obfc2b*^{-/-} cells showed that *Obfc2b* was expressed in wild-type but not in *Obfc2b*^{-/-} cells. However, wild-type and *Obfc2b*^{-/-} cells were otherwise indistinguishable (Supplementary Figure 3C). We conclude that deficiency of *Obfc2b* does not lead to significant changes in osteoblast, chondrocyte or osteoclast gene expression.

Skeletal defects are associated with increased apoptosis

Since the human *Obfc2b* orthologue *hSSB1* has been implicated in DNA repair and DNA repair deficiencies can result in

apoptosis during embryogenesis (Gao *et al*, 1998), we asked whether the skeletal defects in *Obfc2b*^{-/-} embryos were associated with increased apoptosis. To detect apoptotic cells, we performed terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) on tissue sections from E10.5, E12.5 and E16.5 embryos. Whereas E10.5 and E16.5 *Obfc2b*^{-/-} embryos displayed no notable abnormalities (Supplementary Figure 4A and B), E12.5 *Obfc2b*^{-/-} embryos showed significantly increased numbers of apoptotic cells in the developing ribs, hindlimb (HL) bud and branchial arches (BAs) (Figure 3A; Supplementary Figure 4C). This pattern of TUNEL staining is consistent with the majority of the described skeletal defects at E18.5 (see Figure 2).

To determine whether the skeletal defects in *Obfc2b*^{-/-} embryos can be rescued by loss of *p53*, we interbred the two




Figure 3 Increased skeletal apoptosis in *Obfc2b*^{-/-} embryos. (A) *Obfc2b* deficiency is associated with increased apoptosis at E12.5. Terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL) staining of representative tissue sections of E12.5 embryos. Arrows indicate regions of developing branchial arches (BAs), developing ribs and developing hindlimbs (HL). (B) *P53* loss partially rescues skeletal abnormalities in *Obfc2b*^{-/-} embryos. Alcian blue and Alizarin red stained skeletal preparations from P0 *Obfc2b*^{-/-}; *p53*^{+/+}, *Obfc2b*^{-/-}; *p53*^{-/-}, *Obfc2b*^{+/+}; *p53*^{-/-} and *Obfc2b*^{+/+}; *p53*^{+/+} embryos as in Figure 2. Preparations of the rib cage (upper panels), and of the scapula of the forelimb (lower left) and the autopod of the hindlimb (lower right) are shown. (C) Western blot analysis of hind- and forelimbs from E12.5 embryos for phospho-p53 (serine 15), γH2ax, *Obfc2b* and Lamin b1. (D) *In situ* hybridization of whole embryos (E12.5) for *Sox9* mRNA. Upper panels: images of whole embryos are shown including a magnification of the developing scapula. White arrows indicate aberrant *Sox9* staining at the scapula and at the hindlimb. Lower panels: *Sox9* staining of forelimbs (left) and hindlimbs (right).

mutant mouse strains to generate *Obfc2b*^{-/-}; *p53*^{-/-} mice. In contrast to *Obfc2b*^{-/-} newborns that were grossly abnormal and not viable, *Obfc2b*^{-/-}; *p53*^{-/-} mice appeared normal, were viable at birth, and survived up to 24 h. Skeletal preparations from *Obfc2b*^{-/-}; *p53*^{-/-} mice at P0 showed partial rescue of the thoracic rib cage phenotype (Figure 3B, up), and of the forelimb and hindlimb defects (Figure 3B, low). However, the defects in the skull including the cleft palate were not ameliorated and likely account for the perinatal lethality of the *Obfc2b/p53* double knockout pups due to the inability to feed. We conclude that most skeletal defects

in *Obfc2b*^{-/-} embryos are associated with increased apoptosis and, accordingly, can be partially rescued by loss of *p53*.

Skeletal defects are associated with increased genomic instability at E12.5

To investigate whether increased apoptosis in *Obfc2b*^{-/-} embryos results from increased genomic instability, we analysed forelimbs and hindlimbs from E12.5 embryos for γH2ax accumulation and p53 phosphorylation by western blotting because both are induced by and serve as markers for DNA damage (Figure 3C). We found that hindlimbs from *Obfc2b*^{-/-}

embryos showed increased γ H2ax accumulation and p53 phosphorylation at serine 15 (Figure 3C). In contrast, there was only a minimal increase of γ H2ax accumulation and p53 phosphorylation in the forelimbs of *Obfc2b*^{-/-} embryos, which show only minor skeletal defects. We conclude that the skeletal defects in the limbs of *Obfc2b*^{-/-} embryos are associated with and likely to result from increased genomic instability and apoptosis at E12.5.

Defective pre-cartilage condensation at E12.5 in *Obfc2b*^{-/-} embryos

Pre-cartilage mesenchymal condensation precedes the development of chondrocytes and osteoblasts and is essential for the development of skeletal structures (reviewed in Hall and Miyake, 2000 and Kronenberg, 2003). Apoptosis is likely to antagonize pre-cartilage condensation, because defects in skeletogenesis are often associated with increased apoptosis (Akiyama *et al*, 2002; Cheung *et al*, 2005; Shim *et al*, 2010). Conversely, the transcription factor Sox9, which is specifically expressed during condensation in forelimbs and hindlimbs (Wright *et al*, 1995), is thought to suppress apoptosis (Akiyama *et al*, 2002). To analyse if increased apoptosis in *Obfc2b*^{-/-} embryos is associated with defective pre-cartilage condensation we performed *in situ* hybridization for Sox9 on whole embryos at E12.5 (Figure 3D). In agreement with the presence of a minimal skeletal defect in the forelimb of *Obfc2b*^{-/-} embryos, pre-cartilage condensation appeared to be mostly normal in the developing forelimbs of *Obfc2b*^{-/-} embryos (Figure 3D, top and lower left). In contrast, the hindlimbs, which show a high degree of apoptosis and skeletal defects, showed defective pre-cartilage condensation, as did the developing scapula in the forelimb (Figure 3D, up and lower right). We conclude that increased genomic instability and apoptosis in *Obfc2b*^{-/-} embryos is associated with defective pre-cartilage mesenchymal condensation.

***Obfc2b* is dispensable for the DNA damage response in B lymphocytes and MEFs**

Lymphocytes are especially sensitive to defects in the DNA damage response because they undergo programmed DNA damage during V(D)J recombination, and immunoglobulin class-switch recombination (CSR in B cells). As a result, lymphocytes development and function is abnormal in mice or humans that are mutant in any of a number of different factors that contribute to the recognition and repair of DNA damage (reviewed in Rooney *et al*, 2004; Dudley *et al*, 2005 and Jankovic *et al*, 2007). The *Obfc2b* orthologue *hSSB1* has been postulated to be required for the recognition of DNA damage and its repair by the homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways (Richard *et al*, 2008, 2011a,b). To circumvent embryonic lethality and analyse *Obfc2b* function in B cells, we deleted it specifically by combining the conditional allele with a lineage-specific Cre transgene (*CD19*^{Cre};*Obfc2b*^{lox/-} mice). Despite undetectable levels of *Obfc2b* protein in *CD19*^{Cre};*Obfc2b*^{lox/-} B lymphocytes, B cell development in the bone marrow was indistinguishable from control mice (Figure 4A). Likewise, T cell development was indistinguishable in lethally irradiated mice reconstituted with fetal liver cells from wild-type or *Obfc2b*^{-/-} embryos (Figure 4B). Moreover, immunoglobulin CSR in stimulated B cells was

unaffected by loss of *Obfc2b* (Figure 4C). Since CSR and V(D)J recombination require efficient recognition of DNA damage and its repair by the NHEJ pathway we conclude that *Obfc2b* is not required for DNA damage sensing or its repair by NHEJ in lymphocytes.

Poly (ADP-ribose) polymerase (PARP) is required for the detection of single-strand DNA breaks. Inhibiting this enzyme with Ku58948 (PARPi) destabilizes the genome by increasing the number of ssDNA breaks, many of which develop into DSBs that are repaired by HR (Bryant *et al*, 2005; Jackson and Bartek, 2009). Cells defective in HR as well as cells treated with the ATM inhibitor Ku55933 (ATMi) are especially sensitive to PARPi treatment and show reduced proliferation in the presence of PARPi (Bunting *et al*, 2010). To determine whether *Obfc2b* is required for HR, we measured B cell proliferation in the presence or absence of PARPi (Figure 4D). Proliferation was measured by cell division-associated decrease of cytoplasmic staining with carboxyfluorescein succinimidyl ester (CFSE). Cells delayed in proliferation remain CFSE positive after 4 days. *Atm*^{-/-} B cells or wild-type B cells treated with the ATM inhibitor Ku55933 (ATMi) were used as positive controls, and showed a significant increase of cells with delayed proliferation upon PARPi treatment (CFSE-positive cells; Figure 4D and Supplementary Figure 5). However, there was no measurable effect upon loss of *Obfc2b*. We conclude that *Obfc2b* is not required for DNA repair by HR in proliferating B lymphocytes.

To further test if *Obfc2b* is required for the recognition and repair of DNA damage, we irradiated proliferating B cells and analysed metaphases for unrepaired genomic aberrations by fluorescence *in situ* hybridization (FISH). We found only a small and statistically insignificant increase in genomic aberrations in metaphases from activated *Obfc2b*^{-/-} B cells after ionizing irradiation (IR; Figure 4E). We next analysed the frequency of *c-myc/Igh* translocations in proliferating B cells, which are a byproduct of CSR. Defects in recognition and repair of DNA damage typically result in a significant increase in such translocations (Ramiro *et al*, 2006). The frequency of *c-myc/Igh* translocations in proliferating *Obfc2b* deficient B cells was slightly elevated compared to *Obfc2b* proficient cells (Figure 4F). Nevertheless, the translocation frequencies observed fall within the range of what is typically reported for wild-type B cells (Ramiro *et al*, 2004, 2006). We conclude that the *hSSB1* orthologue *Obfc2b* is not required to maintain genomic stability in dividing B lymphocytes.

It has been suggested that *hSSB1* is required for activation of the G1/S and the G2/M DNA damage checkpoint upon irradiation (Richard *et al*, 2008). To determine whether the *hSSB1* orthologue *Obfc2b* is required for the initiation of DNA damage checkpoints *in vivo*, we analysed B cells from *CD19*^{Cre};*Obfc2b*^{lox/-} mice for cell-cycle arrest in response to irradiation. Cells entering mitosis undergo histone 3 phosphorylation at serine 10. Accordingly, histone 3 phosphorylation is abrogated in response to G2/M checkpoint activation. As expected, inhibition of Atm kinase activity using Ku55933 (ATMi) resulted in a reduced activation of the G2/M checkpoint in response to irradiation (Fernandez-Capetillo *et al*, 2002; Figure 5A). However, there was no measurable effect of *Obfc2b* ablation compared to wild-type cells (Figure 5A; Supplementary Figure 6A). Similarly, loss of *Obfc2b* did not affect the G1/S checkpoint




Figure 4 DNA damage response in *Obfc2b^{-/-}* B cells. **(A, B)** Normal B and T cell development in *Obfc2b^{-/-}* mice. **(A)** Flow cytometry analysis of control (*CD19^{Cre};Obfc2b^{+/+}*) and conditional *Obfc2b* knockout (*CD19^{Cre};Obfc2b^{lox/-}*) mice. B cell subsets in the bone marrow were identified using the antibodies indicated. **(B)** Normal T cell development in *Obfc2b^{-/-}* mice. Thymocytes from lethally irradiated mice reconstituted with fetal liver cells from *Obfc2b^{+/+}* or *Obfc2b^{-/-}* embryos. Analysis was performed >2 months after reconstitution. **(C)** Normal class switch-recombination (CSR) in *Obfc2b^{-/-}* B cells. Bar diagram shows mean values of IgG surface expression on conditional *Obfc2b* knockout (*CD19^{Cre};Obfc2b^{lox/-}*) and control B cells (*CD19^{Cre};Obfc2b^{+/+}* and *CD19^{Cre};Obfc2b^{lox/+}*) after 4 days of proliferation *in vitro*, as determined by flow cytometry. IgG1 expression was induced by LPS, IL-4 and RP105 (*) or by LPS and IL-4, IgG3 expression was induced by LPS alone. **(D)** Normal PARPi sensitivity in *Obfc2b^{-/-}* B cells. B cells from *Obfc2b* wild-type mice (*CD19^{Cre};Obfc2b^{+/+}*), conditional *Obfc2b* heterozygous mice (*CD19^{Cre};Obfc2b^{lox/+}*), conditional *Obfc2b* knockout mice (*CD19^{Cre};Obfc2b^{lox/-}*), *Atm^{-/-}* mice or wild-type B cells treated with 2.5 μM Ku55933 (ATMi) were stained with carboxyfluorescein succinimidyl ester (CFSE) and analysed by flow cytometry after 4 days in culture with LPS and IL-4. Cells were cultured with or without 1 μM Ku55948 (PARPi). Bar diagram shows mean values of five individual experiments. Data observed for *Atm^{-/-}* B cells and wild-type B cells treated with ATMi have been pooled. For gating of CFSE-positive cells, see Supplementary Figure 5. **(E)** Normal radiosensitivity in *Obfc2b^{-/-}* B cells. Metaphase analysis of proliferating B cells from control (*CD19^{Cre};Obfc2b^{+/+}* and *CD19^{Cre};Obfc2b^{lox/+}*) and conditional *Obfc2b* knockout mice (*CD19^{Cre};Obfc2b^{lox/-}*) after irradiation with 6 Gy (20 h recovery). Bar diagram shows the mean values of eight pairs of mice analysed in five individual experiments. **(F)** *Obfc2b^{-/-}* B cells exhibit a slight increase of *c-myc/Igh* translocations. PCR analysis of *c-myc/Igh* translocations in B cells from control (*CD19^{Cre};Obfc2b^{+/+}* and *CD19^{Cre};Obfc2b^{lox/+}*) and conditional *Obfc2b* knockout mice (*CD19^{Cre};Obfc2b^{lox/-}*). B cells were cultured for 4 days with LPS and IL-4 previous to analysis. Bar diagram shows the mean of three and four independent experiments for derivative chromosomes 15 and 12, respectively. Data for both derivative chromosomes has been pooled.

as measured by 5-bromo-2'-deoxyuridine (BrdU) incorporation (Figure 5B; Supplementary Figure 6B): Upon IR, *Obfc2b*-deficient cells (KO) were indistinguishable from wild-type

controls in terms of cell-cycle distribution (Figure 5B). Consistent with the absence of cell-cycle checkpoint defects in response to IR, Western blot analysis showed no altera-




Figure 5 DNA damage checkpoint analysis. (A) Normal G2/M checkpoint in *Obfc2b^{-/-}* B cells. Proliferating B cells from wild-type (WT, *CD19^{Cre};Obfc2b^{+/+}*) and conditional knockout (KO, *CD19^{Cre};Obfc2b^{lox/-}*) mice were analysed for histone 3 (serine 10) phosphorylation before and after irradiation (1 h recovery). As a control, wild-type (*CD19^{Cre/+};Obfc2b^{+/+}*) B cells treated with 2.5 μ M Ku55933 (ATMi) were analysed. The graph represents the results from three pairs of mice and two independent experiments. (B) Normal G1/S checkpoint in *Obfc2b^{-/-}* B cells. Proliferating B cells from wild-type (WT, *CD19^{Cre};Obfc2b^{+/+}*) and conditional knockout (KO, *CD19^{Cre};Obfc2b^{lox/-}*) mice were pulsed with BrdU and subjected to cell-cycle analysis. Cells were either mock treated or irradiated with 6 Gy, and allowed to recover for 0.5–24 h. Cells in S phase, G1 and G2 are plotted as individual graphs. Graphs represent the results from three pairs of mice and two independent experiments. (C) Normal IR-induced phosphorylations in *Obfc2b^{-/-}* B cells. Western blot for phosphorylated Atm (serine 1981), Chk1 (serine 317), p53 (serine 15), and for Obfc2b and α Tubulin on lysates from proliferating B cells from *CD19^{Cre};Obfc2b^{lox/+}*, *CD19^{Cre};Obfc2b^{lox/-}* and *Atm^{-/-}* mice. Cells were mock treated or irradiated (12 Gy, 1 h recovery).

tions in IR-induced phosphorylation of Atm, Chk1 (a substrate of Atr) or p53 in the absence of *Obfc2b* (Figure 5C; Supplementary Figure 6C). Similar results were also obtained with *Obfc2b^{-/-}* primary murine embryonic fibroblasts (MEFs; Supplementary Figure 6D and E). Thus, *Obfc2b* is dispensable for Atm/Atr activation and the initiation of DNA damage checkpoints in primary B lymphocytes and embryonic fibroblasts.

Increased *Obfc2a* expression in *Obfc2b*-deficient cells

Obfc2b (orthologue to hSSB1) is homologous with *Obfc2a* (orthologue to hSSB2) and previous studies have suggested that the two may have overlapping functions (Huang *et al*, 2009; Li *et al*, 2009). To determine whether *Obfc2a* might compensate for *Obfc2b* loss, we analysed *Obfc2a* protein levels in tissues of *Obfc2b^{-/-}* embryos (Figure 6A). Western blotting showed that *Obfc2b* deficiency results in




Figure 6 Loss of *Obfc2b* increases expression of *Obfc2a*. (A) Increased *Obfc2a* protein levels in *Obfc2b^{-/-}* embryos. Western blot for *Obfc2a*, *Obfc2b* and Lamin b1 on tissues isolated from E18.5 embryos genotyped as *Obfc2b^{-/-}*, *Obfc2b^{+/-}* and *Obfc2b^{+/+}*. (B) Bar diagram shows relative protein levels of *Obfc2b* and *Obfc2a* detected in five different tissues from wild-type, *Obfc2b^{+/-}* and *Obfc2b^{-/-}* mice measured by western blot normalized to Lamin b1. (C) Increased *Obfc2a* protein levels in *Obfc2b*-deficient MEFs. Bar diagram shows the relative protein levels of *Obfc2b* and *Obfc2a* in primary *Obfc2b^{lox/+};Cre-ERT2* MEFs treated with 5 μ M Tamoxifen (TAM) for 48 h or infected with *Obfc2a*-shRNA expressing lentivirus.

increased *Obfc2a* protein in all tissues tested (Figure 6A and B). Similar results were obtained by deleting *Obfc2b* in *Obfc2b^{lox/-}* primary MEFs carrying a Tamoxifen (TAM) inducible *Cre* transgene (*Obfc2b^{lox/+}; Cre-ERT2*, Figure 6C). In contrast, RNAi-mediated depletion of *Obfc2a* in primary MEFs resulted in only small changes in *Obfc2b* levels (Figure 6C). We conclude that *Obfc2a* protein levels are increased in cells deficient for *Obfc2b*.

Obfc2a is essential for genomic integrity in proliferating MEFs

Obfc2b deficiency does not significantly affect the recognition or repair of DNA damage in B cells, or the initiation of DNA damage checkpoints in B cells and MEFs (see Figures 4 and 5). To determine whether the compensatory increase in expression of *Obfc2a* protein (see Figure 6) masks a defect in these processes, we knocked down *Obfc2a* by RNAi in *Obfc2b*-deficient MEFs. To circumvent elevated levels of *Obfc2a* protein in *Obfc2b*-deficient cells, we first knocked down *Obfc2a* by RNAi in *Obfc2b^{lox/+}; Cre-ERT2* MEFs and subsequently deleted *Obfc2b* using Tamoxifen (Figure 7A).

Knockdown of *Obfc2a* in primary and SV40 transformed MEFs resulted in increased accumulation of γ H2ax as shown by western blotting (Figure 7B; Supplementary Figure 7A) and in an increase in genomic aberrations (Figure 7C). Further, *Obfc2a*-shRNA expressing MEFs failed to expand in culture (Figure 7D). In contrast, Tamoxifen induced deletion of *Obfc2b* did not result in γ H2ax accumulation (Figure 7B; Supplementary Figure 7A), and had only minor effects on proliferation (Figure 7D). Combined depletion of *Obfc2b* and *Obfc2a* did not exacerbate the effects of *Obfc2a* depletion significantly (Figure 7B and D; Supplementary Figure 7A). We conclude that *Obfc2a* is essential for normal replication and maintenance of genomic stability.




Figure 7 Combined loss of *Obfc2b* and *Obfc2a*. (A) Schematic diagram of the sequential knockdown of *Obfc2b* and *Obfc2a* in MEFs: *Obfc2b^{lox/-};Cre-ERT2* MEFs were double infected with lentivirus harbouring either empty vector (control) or *Obfc2a*-shRNA expression vectors. Two to three days after first infection, cells were treated with 5 μ M Tamoxifen (TAM) for 48 h. Analysis was performed 5–6 days after the first infection. (B) *Obfc2a* depletion in MEFs results in γ H2ax accumulation. Western blot of SV40-transformed or primary *Obfc2b^{lox/-};Cre-ERT2* MEFs treated as indicated for *Obfc2b*, *Obfc2a*, γ H2ax and Lamin b1. (C) *Obfc2a* depletion in MEFs results in increased genomic instability. Analysis of metaphase spreads from SV40-transformed MEFs for genomic aberrations 3 days post infection with *Obfc2a*-shRNAs or control vector. 30–50 metaphases have been analysed for each group of infection. The graph represents two independent experiments. (D) *Obfc2a* depletion in MEFs impairs proliferation. Proliferation of SV40-transformed *Obfc2b^{lox/-};Cre-ERT2* MEFs treated as indicated and as described in (A). Diagram represents the mean of two independent experiments. Cell numbers were determined by cell counting. (E) Normal G2/M checkpoint in *Obfc2a* and *Obfc2a/Obfc2b* double deficient MEFs. Bar diagrams show the summary of experiments analysing histone 3 phosphorylation in *Obfc2b^{lox/-};Cre-ERT2* MEFs by flow cytometry. MEFs were treated as in described in (A). Cells were irradiated with 6 Gy and analysed 1 h post irradiation. *Obfc2b* and *Obfc2a* knockdown was verified by western blot in each experiment. (F) Normal IR-induced phosphorylations in *Obfc2a* and *Obfc2a/Obfc2b* double deficient MEFs. Western blot of primary *Obfc2b^{lox/-};Cre-ERT2* MEFs after sequential knockdown of *Obfc2a* and *Obfc2b* as described in (A) for *Obfc2b*, *Obfc2a*, phosphorylated p53 (serine 15), phosphorylated Kap1 (serine 824) and Lamin b1. Cells were mock treated or irradiated as indicated.

Obfc2a is dispensable for the DNA damage response to irradiation in MEFs

To examine the effect of *Obfc2a* deficiency and *Obfc2a/Obfc2b* double deficiency on the induction of the DNA damage response upon irradiation (IR), we measured IR-induced abrogation of histone 3 phosphorylation by flow cytometry (Figure 7E; Supplementary Figure 7B and C) and IR-induced phospho-

rylation of p53, Chk1 and Kap1 by western blot (Figure 7F; Supplementary Figure 7A). In contrast to deletion of *Obfc2b*, depletion of *Obfc2a* resulted in a strong decrease in histone 3 phosphorylation in unirradiated cells (Figure 7E; Supplementary Figure 7B), which was not exacerbated in double deficient cells. This result is in agreement with the proliferation defect observed for *Obfc2a*-depleted cells. Following

irradiation, *Obfc2a*-depleted cells showed a similar reduction in phosphorylated histone 3 as *Obfc2b*-deficient or control cells (Figure 7E; Supplementary Figure 7B and C), and therefore the irradiation-induced G2/M checkpoint appears to be normal in the absence of *Obfc2a*. Even *Obfc2b/Obfc2a* double deficient cells efficiently abrogated histone 3 phosphorylation in response to IR. Analysis of irradiation-induced p53, Chk1 and Kap1 phosphorylation by western blot further indicated a normal DNA damage response in the absence of *Obfc2a* or both, *Obfc2a* and *Obfc2b* (Figure 7F; Supplementary Figure 7A). Lower levels of Chk1 phosphorylation in irradiated *Obfc2a*-depleted cells (Supplementary Figure 7A) correspond to reduced proliferation at the day of analysis (day 5 post infection). This effect is absent at earlier time points after *Obfc2a* depletion when cells are still proliferating (Supplementary Figure 7D). We conclude that even the combined loss of *Obfc2b* and *Obfc2a* does not abrogate the initiation of the DNA damage response in response to irradiation.

Discussion

Previous reports suggested a fundamental role for hSSB1, the protein product of *OBFC2B*, in the recognition and repair of DNA damage (Richard *et al*, 2008, 2011a, b; Huang *et al*, 2009; Li *et al*, 2009; Skaar *et al*, 2009; Zhang *et al*, 2009; Xu *et al*, 2011). Based on RNAi knockdown experiments in human tumour cell lines and neonatal foreskin fibroblasts, hSSB1 was proposed to regulate DNA damage mediated cell-cycle checkpoints and radiosensitivity by binding to DNA breaks, recruiting MRN and activating ATM.

In experiments with mice that carry a null mutation in *Obfc2b* we find no evidence to support the idea that this gene is required for the DNA damage response to irradiation, the activation of Atm or the maintenance of genomic integrity in primary B cells or MEFs. Further, the deficiency of its homologue *Obfc2a* (orthologue to hSSB2) or combined deficiency of *Obfc2b* and *Obfc2a* does not affect the DNA damage response to irradiation.

However, *Obfc2b* seems to play an essential role during embryogenesis. *Obfc2b*^{-/-} mice exhibit growth delay and severe skeletal defects in the skull, limbs and the rib cage. The latter is likely to result in respiratory failure and cause perinatal death of *Obfc2b*^{-/-} embryos. These abnormalities correlate with specific expression of *Obfc2b* in tissues that contribute to bone formation in the embryo and are associated with increased apoptosis at E12.5 in the absence of *Obfc2b*. Apoptosis is in turn associated with accumulation of γ H2ax, suggesting that DNA damage triggers the apoptosis. Consistent with apoptotic cell death as a mechanism for the skeletal abnormalities, we find that many of these defects can be partially rescued by additional loss of *p53*.

Persistence of some developmental defects in *Obfc2b*^{-/-}; *p53*^{-/-} embryos further suggests that *Obfc2b* deficiency can also interfere with normal cellular function beyond the induction of p53-mediated apoptosis during the development of skeletal structures. Since we show that the *Obfc2b* homologue *Obfc2a* is essential for proliferation in MEFs and *Obfc2b* and *Obfc2a* appear to have overlapping functions, it is possible that skeletal defects that are not mediated by *p53* arise as a consequence of an altered proliferation capacity in cells that specifically require *Obfc2b*.




Figure 8 *Obfc2b* supports normal skeletogenesis by suppressing replication-associated DNA damage. Model of *Obfc2b* function during embryogenesis. During the development of pre-cartilage mesenchymal condensation at E12.5 the single-stranded DNA-binding protein *Obfc2b* prevents replication-associated DNA damage. In the absence of *Obfc2b* such DNA damage results in increased apoptosis, which interferes with pre-cartilage condensations. As a consequence, *Obfc2b*^{-/-} embryos develop skeletal defects.

Increased DNA damage and apoptosis in *Obfc2b*^{-/-} embryos is associated with defective pre-cartilage mesenchymal condensation. Apoptosis has been shown to occur before the onset of mesenchymal condensation in many mouse models with skeletal defects (Akiyama *et al*, 2002; Guha *et al*, 2002; Cheung *et al*, 2005; Li *et al*, 2005; Shim *et al*, 2010), and it is likely to prevent condensation. Conversely, expression of the transcription factor *Sox9* has been suggested to favour bone formation by suppressing apoptosis during mesenchymal condensation (Akiyama *et al*, 2002). We propose that *Obfc2b* supports the development of normal skeletal structures by preventing apoptosis arising from replication-associated DNA damage during embryogenesis (Figure 8). *Obfc2b* may do so by protecting ssDNA during replication, which is particularly prone to DNA damage.

Skeletal defects that arise as a consequence of increased genomic instability are not uncommon among human genetic disorders. For example, the Cockayne Syndrome (CS) results from defects in transcription-coupled repair during repair of DNA damage by the nucleotide-excision repair pathway (Venema *et al*, 1990; de Boer and Hoeijmakers, 2000). Besides increased genomic instability, patients suffering from CS exhibit defects in their extremities, the spine and the skull (de Boer and Hoeijmakers, 2000). Similarly, patients suffering from Fanconi Anaemia (FA) or Seckel Syndrome exhibit increased genomic instability and skeletal abnormalities (McKusick *et al*, 1967; Chaganti and Houldsworth, 1991) and reviewed in Kerzendorfer and O'Driscoll (2009). In mice, only the Seckel Syndrome-related mutation leads to skeletal abnormalities (Murga *et al*, 2009) while CS and FA mutations do not. Seckel mice exhibit improper alternative splicing of the *Atr* gene and, as a consequence, Seckel mice express less *Atr* protein, leading to increased replicative stress and increased apoptosis (Murga *et al*, 2009). Similarly to the human disorder, Seckel mice exhibit skeletal defects in the skull. Together, the Seckel and *Obfc2b*^{-/-} mouse models suggest that replication-associated DNA damage and apoptosis are a significant cause for skeletal malformations.

The best-characterized ssDNA-binding protein in eukaryotes is replication protein A (RPA). RPA is primarily recruited to ssDNA lesions that are exposed in collapsed replication forks or resected dsDNA breaks during the S phase of the cell-cycle. RPA recruits ATR and the HR machinery to these lesions (Zou and Elledge, 2003). As might be expected, *Rpa1* mutation in mice predominantly affects

proliferation and the maintenance of genome integrity (Wang *et al*, 2005). In contrast, we show that the ssDNA binding protein *Obfc2b* is not required for proliferation of B lymphocytes or MEFs. However, this analysis is complicated by the finding that *Obfc2b* (*hSSB1*) depletion leads to a compensatory increase in protein of its homologue *Obfc2a* (*hSSB2*), which forms similar heterotrimeric ssDNA-binding complexes as *Obfc2b* (Huang *et al*, 2009; Li *et al*, 2009; Skaar *et al*, 2009; Zhang *et al*, 2009). Furthermore, depletion of *Obfc2a* resulted in a severe impairment in proliferation, γ H2ax accumulation and an increase in genomic aberrations. Therefore, *Obfc2b/Obfc2a* proteins (*hSSB1/hSSB2*) may share common functional characteristics with *Rpa1* including a requirement for these factors in cell division. However, their requirement appears to be cell type specific.

In agreement with previous studies we find that deficiency of *Obfc2b* (*hSSB1*) or *Obfc2a* (*hSSB2*) results in genomic instability and in a reduction in phosphorylated histone 3 (Richard *et al*, 2008; Zhang *et al*, 2009). Moreover deletion of *Obfc2b* results in a compensatory increase in *Obfc2a* protein (Huang *et al*, 2009). However, *hSSB1* has also been reported to control the G1/S and G2/M DNA damage checkpoints, ATM activation, and the repair of DNA damage by NHEJ and HR (Richard *et al*, 2008; Huang *et al*, 2009). None of these is altered by *Obfc2b* deletion in mice, or by *Obfc2a* knockdown in our experiments. However, our work differs from previous experiments in that the latter were performed using continuously growing cell lines, which may have acquired defective DNA damage responses while undergoing transformation (e.g., Broceno *et al*, 2002). We speculate that such additional abnormalities made the cultured cells more prone to show defects in cell-cycle checkpoints or the DNA damage response after depletion of *hSSB1*.

In summary, we report an essential, unique and cell type-specific role of the *hSSB1* orthologue *Obfc2b* during embryogenesis. Loss of *Obfc2b* results in apoptosis of cell lineages that are essential for skeletal development and depend on *Obfc2b*. Moreover, *Obfc2b* and its homologue *Obfc2a* (orthologue to *hSSB2*) appear to be co-regulated in that loss of *Obfc2b* leads to a compensatory increase in *Obfc2a* protein. These ssDNA-binding proteins are not required to initiate the DNA damage response to irradiation, but together play an important role in normal cellular proliferation and the suppression of replication-associated DNA damage. Proliferation defects and replication-associated DNA damage are likely to result in apoptosis in rapidly dividing cells as observed during early embryogenesis in select domains of *Obfc2b*^{-/-} embryos.

Materials and methods

Mice

Obfc2b^{lox/+} mice were produced by HR in C57BL/6 albino ES cells. Details on the targeting vector, screening by Southern blot, and genotyping PCR are provided in the legends to the Supplementary Figures. *FLPe* (a gift by Dr Susan Dymecki; Rodriguez *et al*, 2000), *EIIA*^{Cre} (Lakso *et al*, 1996), *CD19*^{Cre} (Rickert *et al*, 1997), *Cre-ERT2* (de Luca *et al*, 2005), *Atm*^{-/-} (Barlow *et al*, 1996), and *p53*^{-/-} mice (Jacks *et al*, 1994) were used for breeding with *Obfc2b*^{NEO-lox/+}, *Obfc2b*^{lox/+} or *Obfc2b*^{+/-} mice as indicated. All experiments were in agreement with protocols approved by the Rockefeller University and National Institutes of Health (NIH) Institutional Animal Care and Use Committee.

Fetal liver transfer

Fetal liver transfers were performed with SJL mice as hosts (The Jackson Laboratory) as described in Horwitz *et al* (1997), with the exception that mice were irradiated with a dose of 2×500 rad with a 3-h recovery between each irradiation and before injection.

MEF culture and shRNA infection

Primary MEFs were isolated from E12.5 embryos and frozen as aliquots at passage 2 (1 week). Immortalized MEFs were generated by infection with SV40 large T retrovirus at 2 weeks of cell culture. Viral supernatant was generated as described in Robbani *et al* (2008). Lentiviral supernatant was produced by transfection of 293T cells with Δ 8.9 and VSV encoding helper plasmids (Naldini *et al*, 1996) and either empty vector (pLKO-IRES-GFP; Open Biosystems) or *Obfc2a*-shRNA encoding expression vectors (TRCN0000177652 [sh1], TRCN0000178020 [sh2]; Open Biosystems). 4-Hydroxytamoxifen (TAM) was from Sigma.

Tissue sections and TUNEL analysis

Frozen tissue sections were prepared from E10.5 and E12.5 embryos as described (Lindquist *et al*, 2004). Tissue sections from E16.5 embryos were prepared by paraffin embedding and further sectioning by the Laboratory of Comparative Pathology (Rockefeller University). TUNEL of tissue sections was performed using the *In Situ* Cell Death Detection Kit, TMR red (Roche).

B cell cultures

Primary B cells were isolated from spleen and treated as described (Bothmer *et al*, 2010). B cells were kept in culture with 25 μ g/ml lipopolysaccharide (LPS) (Sigma) and 5 ng/ml of mouse recombinant interleukin 4 (IL-4) (Sigma) for 4 days and percentage of immunoglobulin (Ig) switching was measured by flow cytometry. If indicated, 0.5 μ g/ml RP105 (RP/14, BD) was added to the culture medium. Irradiation was performed after 48 h of culture using the dosages and recovery times indicated. CFSE (Molecular Probes) labelling for proliferation analysis was performed as described in Bothmer *et al* (2010). PARP inhibitor (PARPi, Ku58948) and ATM inhibitor (ATMi, Ku55933) were from KuDOS and used at a concentration of 1 and 2.5 μ M, respectively.

DNA damage checkpoint analysis

For the analysis of G2/M arrest, irradiated or mock-treated cells were stained using an anti-phosphorylated histone 3 (serine 10, clone D2C8) antibody (Cell Signaling) according to manufacturer's instructions. For the analysis of G1/S arrest, the APC-BrdU flow kit was used (BD). B cells were irradiated at 48 h of culture with LPS and IL-4 and harvested at time points indicated.

Western blot

Western blot was performed as described in Feldhahn *et al* (2005). The following antibodies were used: Anti-phospho-Histone H2a.x (serine 139) clone JBW301 (Millipore), anti-phospho-Atm (serine 1981) (Rockland), anti-phospho-Chk1 (serine 317) (R&D), anti-phospho-p53 (serine 15) (Cell Signaling), anti- α Tubulin (Abcam), anti-Lamin b1 (Abcam), anti-*hSSB1* (Bethyl Laboratories), anti-*Obfc2a* (Proteintech Group) and anti-phospho-Kap1 (serine 824) (Bethyl Laboratories).

Flow cytometry

Single cell suspensions from bone marrow, spleen or thymus were obtained as described (Robbani *et al*, 2008) and stained using the following antibodies: B220-PE, B220-APC, B220-PerCPcy5, Cd19-APC, IgM-PE, IgD-FITC, Cd3-PE, Cd8-PE, Cd4-FITC, Cd42.2-PerCPcy5, TCR γ / δ -PE, TCR α / β -FITC (BD). For analysis of CSR, an anti-IgG1-APC antibody (BD) or an anti-IgG3-biotin antibody (Southern Biotech) in combination with Streptavidin-APC (BD) was used.

Metaphase spreads analysis

Metaphase spreads were prepared and imaged as described (Callen *et al*, 2007). B cells were incubated for 1 h with 0.1 μ g/ml Colcemid (Roche) before metaphase preparation; MEFs were incubated for 3 h with Colcemid.

***c-myc/Igh* translocation analysis**

PCR analysis of *c-myc/Igh* translocations was performed as described in Robbiani *et al* (2008). In brief, genomic DNA (gDNA) from B cells stimulated with 25 µg/ml LPS (Sigma) and 5 ng/ml mouse recombinant IL-4 (Sigma) for 4 days was extracted, and 500 ng gDNA (equivalent of 100 000 cells) was used in each PCR. After gel electrophoresis of PCR products, agarose gels were subjected to Southern blotting. Bands detected by both a *c-myc* and an *Igh* probe were scored as translocation.

Skeletal preparations

Skeletal preparations and staining with Alcian blue (Sigma) and Alizarin red (Sigma) to visualize cartilage and bone/mineralized tissue was performed on day E18.5 p.c. or P0 embryos as indicated according to McLeod (1980), Selleri *et al* (2001) and Ferretti *et al* (2011).

Micro-computer tomography

P0 embryos were formalin embedded and subjected to MicroCT. In all, 3.5 µm voxel size, 45KVp, 0.36 degrees rotation step, 180 degrees angular range, 400 ms exposure and 1 averaged frame per view were used for the scans, which were performed in air. The Scanco µCT software (HP, DECwindows Motif 1.6) was used for 3D reconstruction, evaluation and viewing of images. After 3D reconstruction, the volumes of interest were segmented and analysed using a global threshold of 0.3 g/ccm. Directly measured bone volume fraction (BV/TV) and tissue mineral density (TMD) were calculated for mid-diaphysis for estimating the differences between *Obfc2b*^{+/+} and *Obfc2b*^{-/-} embryos.

In situ hybridization

Whole-mount *in situ* hybridization on E10.5 and E12.5 embryos and probe purification was performed as described (Ferretti *et al*, 2011, Selleri *et al*, 2001). Murine *Obfc2b* mRNA-specific sense and anti-sense probes were produced by PCR amplification of the last exon and 3'UTR of *Obfc2b* using 5'-TTCCGAGAACCAGAACGG-3' as forward and 5'-AAGGAGGGCAGGCAGAGG-3' as reverse primer on cDNA from wild-type B cells. The PCR product was ligated into the pCR4-TOPO vector (Invitrogen) and the plasmid sequenced and linearized using Pmel (NEB) or NotI (NEB). *Sox9* probes were produced using a *Sox9* cDNA encoding plasmid (Wright *et al*, 1995). Digoxigenin (DIG)-labelled sense and anti-sense probes were produced by *in vitro* transcription using T3 and T7 primers and the DIG RNA labeling kit (Roche).

Isolation of chondrocytes, osteoblasts and osteoclasts and gene array analysis

Primary chondrocytes were isolated from the sternum of E18.5 p.c. old mice by pronase and collagenase treatment as described in

Lefebvre *et al* (1994) and Retting *et al* (2009). After expanding for 7 days in cell culture, chondrocytes were harvested by trypsinization. Primary osteoblasts were isolated from E18.5 p.c. old mice from the part of the calvaria of the skull that has been identified in the skeletal preparations to be already mineralized (Alizarin Red staining, see Figure 2B). Calvaria plates were then pre-digested twice by 0.1 mg/ml collagenase in aMEM medium at 37°C for 15 min. Bone plates were then cultured in aMEM medium (Invitrogen) + 10% fetal calf serum + 1% Penicillin/Streptomycin (Invitrogen) for 13 days and outgrowing osteoblasts were harvested by trypsinization. Osteoclasts were isolated by culturing erythrocyte-depleted bone marrow cells from the femur in αMEM medium + 10% fetal calf serum + 1% Penicillin/Streptomycin including 20 ng/ml murine M-CSF (PeproTech) for 24 h. Non-adherent cells were transferred to new media containing 30 ng/ml murine M-CSF and 40 ng/ml RANK-L (PeproTech) and cultured for 5 more days. Media was replaced by fresh media every 2 days. Multinucleated giant cells were stained by TRAP staining (Sigma-Aldrich) to verify osteoclast identity. RNA was extracted from 2.5 × 10⁶ chondrocytes and osteoblasts, and from one 10 cm dish for osteoclasts using Trizol (Invitrogen). RNA was subjected to whole genome gene expression analysis using the MouseRef-8 v2.0 Expression BeadChip (Illumina). Data was analysed using GeneSpring GX software.

Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

Acknowledgements

All members of the Nussenzweig laboratory for discussions. Klara Velinzo for cell sorting. The Rockefeller University Gene Targeting Facility for the generation of mutant mice. The work was supported by an NIH grant to MCN (R01 AI037526-18) and an NIH grant to LS (R01 HD043997). NF was a Fellow of the Leukemia and Lymphoma Society. MCN is a Howard Hughes Medical Institute Investigator.

Author contributions: NF designed and performed most experiments. EF performed skeletal preparations on E18.5 embryos and assisted in *in situ* hybridizations. DFR assisted in the design of the *Obfc2b*^{fllox} targeting vector. SD helped on metaphase preparations. EC performed the analysis of all prepared metaphase spreads. LS supervised experiments performed on embryos. AN and MCN supervised all experiments. NF and MCN wrote the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrughe B (2002) The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. *Genes Dev* **16**: 2813–2828
- Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A (1996) Atm-deficient mice: a paradigm of ataxia telangiectasia. *Cell* **86**: 159–171
- Bothmer A, Robbiani DF, Feldhahn N, Gazumyan A, Nussenzweig A, Nussenzweig MC (2010) 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. *J Exp Med* **207**: 855–865
- Broceno C, Wilkie S, Mittnacht S (2002) RB activation defect in tumor cell lines. *Proc Natl Acad Sci USA* **99**: 14200–14205
- Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**: 913–917
- Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM, Nussenzweig A (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. *Cell* **141**: 243–254
- Callen E, Jankovic M, Difiippantonio S, Daniel JA, Chen HT, Celeste A, Pellegrini M, McBride K, Wangsa D, Bredemeyer AL, Sleckman BP, Ried T, Nussenzweig M, Nussenzweig A (2007) ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. *Cell* **130**: 63–75
- Chaganti RS, Houldsworth J (1991) Fanconi anemia: a pleotropic mutation with multiple cellular and developmental abnormalities. *Ann Genet* **34**: 206–211
- Cheung M, Chaboissier MC, Mynett A, Hirst E, Schedl A, Briscoe J (2005) The transcriptional control of trunk neural crest induction, survival, and delamination. *Dev Cell* **8**: 179–192
- de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. *Carcinogenesis* **21**: 453–460
- de Luca C, Kowalski TJ, Zhang Y, Elmquist JK, Lee C, Kilimann MW, Ludwig T, Liu SM, Chua Jr SC (2005) Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. *J Clin Invest* **115**: 3484–3493
- Dudley DD, Chaudhuri J, Bassing CH, Alt FW (2005) Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. *Adv Immunol* **86**: 43–112

- Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Muschen M (2005) Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. *J Exp Med* **201**: 1837–1852
- Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, Carpenter PB, Bonner WM, Chen J, Nussenzweig A (2002) DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. *Nat Cell Biol* **4**: 993–997
- Ferretti E, Li B, Zewdu R, Wells V, Hebert JM, Karner C, Anderson MJ, Williams T, Dixon J, Dixon MJ, Selleri L (2011) A conserved Pbx-Wnt-p63-Irf6 regulatory module controls face morphogenesis by promoting epithelial apoptosis. *Dev Cell* **21**: 627–641
- Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ, Sekiguchi JM, Rathbun GA, Swat W, Wang J, Bronson RT, Malynn BA, Bryans M, Zhu C, Chaudhuri J, Davidson L, Ferrini R, Stamato T, Orkin SH, Greenberg ME et al (1998) A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. *Cell* **95**: 891–902
- Guha U, Gomes WA, Kobayashi T, Pestell RG, Kessler JA (2002) In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb. *Dev Biol* **249**: 108–120
- Hall BK, Miyake T (2000) All for one and one for all: condensations and the initiation of skeletal development. *Bioessays* **22**: 138–147
- Horwitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D (1997) Failure of lymphopoiesis after adoptive transfer of NF-kappaB-deficient fetal liver cells. *Immunity* **6**: 765–772
- Huang J, Gong Z, Ghosal G, Chen J (2009) SOSS complexes participate in the maintenance of genomic stability. *Mol Cell* **35**: 384–393
- Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. *Curr Biol* **4**: 1–7
- Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. *Nature* **461**: 1071–1078
- Jankovic M, Nussenzweig A, Nussenzweig MC (2007) Antigen receptor diversification and chromosome translocations. *Nat Immunol* **8**: 801–808
- Kerzendorfer C, O'Driscoll M (2009) Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency. *DNA Repair (Amst)* **8**: 1139–1152
- Kronenberg HM (2003) Developmental regulation of the growth plate. *Nature* **423**: 332–336
- Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. *Proc Natl Acad Sci USA* **93**: 5860–5865
- Lefebvre V, Garofalo S, Zhou G, Metsaranta M, Vuorio E, De Crombrughe B (1994) Characterization of primary cultures of chondrocytes from type II collagen/beta-galactosidase transgenic mice. *Matrix Biol* **14**: 329–335
- Li C, Xu X, Nelson DK, Williams T, Kuehn MR, Deng CX (2005) FGFR1 function at the earliest stages of mouse limb development plays an indispensable role in subsequent autopod morphogenesis. *Development* **132**: 4755–4764
- Li Y, Bolderson E, Kumar R, Muniandy PA, Xue Y, Richard DJ, Seidman M, Pandita TK, Khanna KK, Wang W (2009) HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. *J Biol Chem* **284**: 23525–23531
- Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, Nussenzweig MC (2004) Visualizing dendritic cell networks in vivo. *Nat Immunol* **5**: 1243–1250
- McKusick VA, Mahloudji M, Abbott MH, Lindenberg R, Kepas D (1967) Seckel's bird-headed dwarfism. *N Engl J Med* **277**: 279–286
- McLeod MJ (1980) Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. *Teratology* **22**: 299–301
- Mendez J, Stillman B (2003) Perpetuating the double helix: molecular machines at eukaryotic DNA replication origins. *Bioessays* **25**: 1158–1167
- Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M, Lee Y, McKinnon PJ, Nussenzweig A, Fernandez-Capetillo O (2009) A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. *Nat Genet* **41**: 891–898
- Naldini L, Blomer U, Gally P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* **272**: 263–267
- Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, Eisenreich TR, Chen J, Dickins RA, Lowe SW, Nussenzweig A, Nussenzweig MC (2006) Role of genomic instability and p53 in AID-induced c-myc-IgH translocations. *Nature* **440**: 105–109
- Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, Honjo T, Nussenzweig A, Nussenzweig MC (2004) AID is required for c-myc/IgH chromosome translocations in vivo. *Cell* **118**: 431–438
- Retting KN, Song B, Yoon BS, Lyons KM (2009) BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. *Development* **136**: 1093–1104
- Richard DJ, Bolderson E, Cubeddu L, Wadsworth RI, Savage K, Sharma GG, Nicolette ML, Tsvetanov S, McIlwraith MJ, Pandita RK, Takeda S, Hay RT, Gautier J, West SC, Paull TT, Pandita TK, White MF, Khanna KK (2008) Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. *Nature* **453**: 677–681
- Richard DJ, Cubeddu L, Urquhart AJ, Bain A, Bolderson E, Menon D, White MF, Khanna KK (2011a) hSSB1 interacts directly with the MRN complex stimulating its recruitment to DNA double-strand breaks and its endo-nuclease activity. *Nucleic Acids Res* **39**: 3643–3651
- Richard DJ, Savage K, Bolderson E, Cubeddu L, So S, Ghita M, Chen DJ, White MF, Richard K, Prise KM, Schettino G, Khanna KK (2011b) hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex. *Nucleic Acids Res* **39**: 1692–1702
- Rickert RC, Roes J, Rajewsky K (1997) B lymphocyte-specific, Cre-mediated mutagenesis in mice. *Nucleic Acids Res* **25**: 1317–1318
- Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio S, Bolland DJ, Chen HT, Corcoran AE, Nussenzweig A, Nussenzweig MC (2008) AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell* **135**: 1028–1038
- Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R, Stewart AF, Dymecki SM (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. *Nat Genet* **25**: 139–140
- Rooney S, Chaudhuri J, Alt FW (2004) The role of the non-homologous end-joining pathway in lymphocyte development. *Immunol Rev* **200**: 115–131
- Selleri L, Depew MJ, Jacobs Y, Chanda SK, Tsang KY, Cheah KS, Rubenstein JL, O'Gorman S, Cleary ML (2001) Requirement for Pbx1 in skeletal patterning and programming chondrocyte proliferation and differentiation. *Development* **128**: 3543–3557
- Shim M, Foley J, Anna C, Mishina Y, Eling T (2010) Embryonic expression of cyclooxygenase-2 causes malformations in axial skeleton. *J Biol Chem* **285**: 16206–16217
- Skaar JR, Richard DJ, Saraf A, Toschi A, Bolderson E, Florens L, Washburn MP, Khanna KK, Pagano M (2009) INTS3 controls the hSSB1-mediated DNA damage response. *J Cell Biol* **187**: 25–32
- Venema J, Mullenders LH, Natarajan AT, van Zeeland AA, Mayne LV (1990) The genetic defect in Cockayne syndrome is associated with a defect in repair of UV-induced DNA damage in transcriptionally active DNA. *Proc Natl Acad Sci USA* **87**: 4707–4711
- Wang Y, Putnam CD, Kane MF, Zhang W, Edelmann L, Russell R, Carrion DV, Chin L, Kucherlapati R, Kolodner RD, Edelmann W (2005) Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. *Nat Genet* **37**: 750–755
- Wright E, Hargrave MR, Christiansen J, Cooper L, Kun J, Evans T, Gangadharan U, Greenfield A, Koopman P (1995) The Sry-related gene Sox9 is expressed during chondrogenesis in mouse embryos. *Nat Genet* **9**: 15–20
- Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H, Lv X, Hu K, Cao J, Zhang R, Chen L, Liu M, Yun JP, Zeng YX, Kang T (2011) hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. *Oncogene* **30**: 2219–2229
- Zhang F, Wu J, Yu X (2009) Integrator3, a partner of single-stranded DNA-binding protein 1, participates in the DNA damage response. *J Biol Chem* **284**: 30408–30415
- Zou L, Elledge SJ (2003) Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* **300**: 1542–1548